Lotus Pharmaceuticals, Inc.

Total Valuation

Lotus Pharmaceuticals, Inc. carries a market capitalization of 98,773.00, placing it among publicly traded companies globally. Its enterprise value stands at 15.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Lotus Pharmaceuticals, Inc. currently has 27.80M shares outstanding.

Valuation Ratios

Lotus Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 6.06. The price-to-sales ratio is 0.15, and the price-to-book ratio stands at 0.18.

Enterprise Valuation

On an enterprise value basis, Lotus Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 1.62 and an EV/FCF ratio of 0.42. The EV/Sales ratio of 0.22 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 2.08 provides insight into valuation relative to core operating earnings.

Financial Position

Lotus Pharmaceuticals, Inc. maintains a current ratio of 0.53, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.44, indicating elevated leverage, while an interest coverage ratio of 39.12 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Lotus Pharmaceuticals, Inc. has paid -250,073.00 in income taxes, reflecting an effective tax rate of 0.01.

Stock Price Statistics

Lotus Pharmaceuticals, Inc.'s stock has declined approximately -38.98305% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Income Statement

Over the trailing twelve months, Lotus Pharmaceuticals, Inc. generated 70.79M in revenue and converted that into 1.74M in net income, yielding earnings per share of 0.06. EBITDA reached 9.71M, while operating income came in at 7.57M.

Balance Sheet

Lotus Pharmaceuticals, Inc. holds 158,908.00 in cash and equivalents against 5.41M in total debt, resulting in a net debt position of 5.25M. Total book value stands at 59.20M, with working capital of -6.64M providing operational flexibility.

Cash Flow

Lotus Pharmaceuticals, Inc. produced 18.37M in operating cash flow over the past twelve months. After subtracting -19.17M in capital expenditures, free cash flow totaled -802,955.00 - equivalent to -0.03 per share.

Margins

Lotus Pharmaceuticals, Inc. operates with a gross margin of 35.10, reflecting its pricing power and cost economics. The operating margin of 10.69 and net profit margin of 2.45 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Lotus Pharmaceuticals, Inc.'s most recent stock split took place on December 31, 2010 with a 2:1 split ratio.

Scores

Lotus Pharmaceuticals, Inc. posts an Altman Z-Score of 1.82, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.